Research Associate - Preclinical/In Vivo
GC Therapeutics
Summary
GC Therapeutics is seeking a talented and highly motivated Research Associate to join our Preclinical team. The successful candidate will support the advancement of GC Therapeutics' therapeutic pipeline through hands-on execution of in vitro and in vivo studies. This role is well suited for an early-career scientist with a strong interest in learning about preclinical drug development and conducting hands-on laboratory and animal research.
Job description
Duties and Responsibilities
- Execute rodent in vivo studies, including handling, dosing, monitoring, necropsy, tissue collection, and tissue processing.
- Support colony maintenance and genotyping.
- Perform tissue sectioning, immunohistochemistry/immunofluorescence, microscopy, and image analysis.
- Maintain mammalian cell cultures and perform molecular and cell-based assays, including DNA/RNA extraction, PCR, and flow cytometry.
- Analyze and summarize experimental data, preparing figures and presentations for internal meetings.
- Maintain accurate laboratory and animal records in accordance with SOPs, study protocols, and safety requirements.
- Collaborate across research teams, including occasional weekend coverage for animal studies and cell culture.
Essential Qualifications
- Bachelor's degree in biology, biomedical sciences, or a related field.
- 1–3 years of relevant laboratory experience in an academic, biotechnology, pharmaceutical, or CRO setting; strong undergraduate research or internship experience may be considered.
- Hands-on rodent experience, including basic handling and some exposure to dosing, tissue collection, surgery, or other in vivo procedures.
- Experience with tissue processing, immunohistochemistry or immunofluorescence, and microscopy.
- Experience with mammalian cell culture and core molecular biology techniques such as DNA/RNA extraction and PCR.
- Meticulous attention to detail, with the organizational discipline to follow protocols precisely, document work thoroughly, and manage multiple experiments at once.
- Availability for occasional weekend responsibilities.
Preferred Qualifications
- Experience with rodent models of neurological or neurodegenerative disease.
- Experience with stereotaxic surgery or CNS dosing in rodents.
- Experience with CNS tissue collection, cryosectioning, or confocal microscopy.
- Experience with flow cytometry or other cell-based characterization assays.
- Experience maintaining or differentiating pluripotent stem cells, including iPSCs.
- Familiarity with animal colony management and genotyping.
Requirements
- Bachelor's degree in biology, biomedical sciences, or a related field
- 1–3 years of relevant laboratory experience in an academic, biotechnology, pharmaceutical, or CRO setting; strong undergraduate research or internship experience may be considered
- Hands-on rodent experience, including basic handling and some exposure to dosing, tissue collection, surgery, or other in vivo procedures
- Experience with tissue processing, immunohistochemistry or immunofluorescence, and microscopy
- Experience with mammalian cell culture and core molecular biology techniques such as DNA/RNA extraction and PCR
- Meticulous attention to detail, with the organizational discipline to follow protocols precisely, document work thoroughly, and manage multiple experiments at once
- Availability for occasional weekend responsibilities
Benefits
- Paid Time Off
- Paid Holidays
- Medical Insurance
- Dental Insurance
- Vision Insurance
- 401(k)
- Life Insurance
- Disability Insurance
- Transportation Subsidy
- Annual Bonus
- Equity Awards
Company overview
GC Therapeutics (GCTx) is a biotechnology company headquartered in Cambridge, Massachusetts, dedicated to scaling and unlocking the next generation of cell therapy-based medicines. The company was founded in 2019 based on groundbreaking research from Professor George Church's lab at Harvard Medical School and the Wyss Institute. GCTx has developed TFome™ (Transcription-Factor-ome), the world's first "plug-and-play" induced pluripotent stem cell (iPSC) cellular programming platform that integrates synthetic biology, gene editing, cell engineering, and machine learning. This innovative platform enables the rapid and efficient production of fully optimized iPSC-based cell therapies through a streamlined, single-step process that is up to 100 times faster than conventional methods, with improved potency, efficiency, quality, and cost-effectiveness. The company is advancing a pipeline of potential best-in-class cell therapy programs targeting gastrointestinal, neurological, and immunological diseases. GCTx has raised $75 million to date, including a $65 million Series A financing led by Cormorant Asset Management with participation from a16z Bio + Health, Mubadala Capital, and other leading life sciences investors.